Press release
Triple Negative Breast Cancer Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
Upcoming therapies, such as TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics), and others, have the potential to create a significant positive shift in the TNBC market size and the treatment scenario.
"Triple Negative Breast Cancer Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Triple Negative Breast Cancer Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Triple Negative Breast Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Triple Negative Breast Cancer Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Triple Negative Breast Cancer treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Triple Negative Breast Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Triple Negative Breast Cancer Therapeutics Domain:
https://www.delveinsight.com/report-store/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Triple Negative Breast Cancer Therapeutics Analysis
Currently, the treatment paradigm for TNBC includes a few treatment options, such as systemic chemotherapies, neoadjuvant or adjuvant chemotherapy, surgery, and radiation. The Triple Negative Breast Cancer market holds few US FDA-approved drugs, such as KEYTRUDA (pembrolizumab) by Merck Sharpe and Dohme, LYNPARZA (olaparib) by AstraZeneca, TRODELVY (sacituzumab govitecan) by Gilead Sciences, etc. However, various off-label drugs are used for treating TNBC, which include Paclitaxel (Abraxane), Erbulin (Halaven), Carboplatin, Cisplatin, Docetaxel, etc. To further improve the treatment scenario, several major pharma and biotech giants are actively working in the Triple Negative Breast Cancer Therapeutics market.
The Leading Players in the Triple Negative Breast Cancer Therapeutics Market Include:
• Astellas
• AstraZeneca
• Clovis Oncology
• CytoDyn
• Gilead Science
• HiberCell
• Hoffmann-La Roche
• Immunomedics
• Imprime PGG
• Infinity Pharmaceuticals
• Merck
• Roche
• Tesaro
And Many Others
Triple Negative Breast Cancer Emerging and Marketed Therapies Covered in the Report Include:
• Atezolizumab: Roche
• Capitasertib: AstraZeneca
• Cobimetinib: Roche
• Enzalutamide: Pfizer/Astellas
• HiberCell: Imprime PGG
• Ipatasertib: Roche
• IPI-549 (Eganelisib): Infinity Pharmaceuticals
• KEYTRUDA (pembrolizumab): Merck & Co
• Niraparib: Tesaro
• Pembrolizumab: Merck
• Rucaparib: Clovis Oncology
• Sacituzumab Govitecan: Immunomedics
• TRODELVY (sacituzumab govitecan-hziy): Gilead Sciences
• HiberCell: Imprime PGG
• MDNA11: Medicenna Therapeutics
• Leronlimab (PRO 140): CytoDyn
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Triple Negative Breast Cancer Current Treatment Patterns
4. Triple Negative Breast Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Triple Negative Breast Cancer Late-Stage Products (Phase-III)
7. Triple Negative Breast Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Triple Negative Breast Cancer Discontinued Products
13. Triple Negative Breast Cancer Product Profiles
14. Triple Negative Breast Cancer Key Companies
15. Triple Negative Breast Cancer Key Products
16. Dormant and Discontinued Products
17. Triple Negative Breast Cancer Unmet Needs
18. Triple Negative Breast Cancer Future Perspectives
19. Triple Negative Breast Cancer Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Triple Negative Breast Cancer Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical and Non-Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies here
News-ID: 2977695 • Views: 1390
More Releases from DelveInsight Business Research LLP
Fungal Pneumonia Market to Witness Growth by 2032, Estimates DelveInsight
DelveInsight's "Fungal Pneumonia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Fungal Pneumonia, historical and forecasted epidemiology as well as the Fungal Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Fungal Pneumonia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Fungal Pneumonia market size…
Pseudomonas Aeruginosa Infection Market to Witness Growth by 2032, Estimates Del …
DelveInsight's "Pseudomonas Aeruginosa Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Pseudomonas Aeruginosa Infection, historical and forecasted epidemiology as well as the Pseudomonas Aeruginosa Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Pseudomonas Aeruginosa Infection market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted…
Coagulation Factor Deficiency Market to Witness Growth by 2032, Estimates DelveI …
DelveInsight's "Coagulation Factor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Coagulation Factor Deficiency, historical and forecasted epidemiology as well as the Coagulation Factor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Coagulation Factor Deficiency market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted…
Dental Equipment Market to Witness a Robust Growth in the Upcoming Years, Assert …
DelveInsight's "Dental Equipment Market Insight & Forecast" report will offer an in-depth understanding of the Dental Equipment market, further benefiting the competitors or stakeholders operating in the Dental Equipment arena.
Read more about Dental Equipment Market Report Offerings @ https://www.delveinsight.com/report-store/dental-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
The Dental Equipment market report provides an overview of Dental Equipment, applications of Dental Equipment as well as its advantages and limitations. Additionally, the report provides insight on the Dental Equipment market…
More Releases for Triple
Triple Net Lease Properties And Tenants
Aug 26, 2019 - A triple net or NNN lease is a single-tenant arrangement that requires the tenant to pay all operating expenses associated with the property they've rented. NNN investors enjoy a regular flow of income without any liabilities as all additional expenses are covered by the tenant. This kind of investment is suitable for investors who don't want to spend time and money in the maintenance of their…
TRIPLE TRIPADVISOR SUCCESS FOR ANOKI RESTAURANT
Anoki has reinforced its reputation as one of the UK’s leading fine dining restaurants after all three restaurants were inducted into TripAdvisor’s coveted Hall of Fame.
The restaurants in Derby, Nottingham and Burton have received the accolade after being awarded the prestigious Certificate of Excellence for five consecutive years.
Now in its ninth year, The TripAdvisor Certificate of Excellence celebrates hospitality businesses that are consistently excellent – having earned great traveller reviews…
Triple award winning awning model
Cassette awning markilux 970 now also awarded iF Design Award
In autumn, last year, awning expert markilux already enjoyed the success of its new cassette awning, the markilux 970. Already in the first year it managed to receive two design awards. At the beginning of 2014 a third award followed: the internationally renowned iF Design Award. More than 5,000 registrations from 59 countries participated in the competition in 2016.
According to…
Panthong Manichanh Launches Triple M Designz
FOR IMMEDIATE RELEASE
Panthong Manichanh Launches Triple M Designz
Triple M Designz to provide videography, multimedia and graphic arts services to musicians, entertainers and entrepreneurs.
San Diego, California, August 23, 2011 Panthong Manichanh today announced the launch of Triple M Designz. Triple M Designz will provide a unique combination of video production, graphic design, photography, and promotional art, ranging from designing logos, developing brands, designing album cover, and filming and producing videos for…
Triple Diamond Energy Corp. Strikes Oil
Triple Diamond Energy Corp., a Texas-based independent oil and gas drilling company, recently struck natural gas and oil at the McClure Diamond Well #3.
ADDISON, TX - Triple Diamond Energy Corporation (TDEC), an oil and gas drilling company based in Texas, recently struck oil and natural gas at the McClure Diamond Well #3 located in Garvin County, Oklahoma. When the well was opened, it produced at a flow rate of as…
Triple Diamond Energy Corp. Begins Triple Diamond Energy No. 2 Joint Venture
Triple Diamond Energy Corp., a Texas-based independent oil and gas drilling company, is currently preparing to drill the No. 2 Joint Venture oil project.
ADDISON, TX -- Texas-based oil and gas exploration and production company, Triple Diamond Energy Corp., has announced that it is now in the planning stages of the Triple Diamond Energy No. 2 Joint Venture oil well project. The project consists of plans to drill four development wells.…
